125.63
0.64 (0.51%)
| Previous Close | 124.99 |
| Open | 126.50 |
| Volume | 927,095 |
| Avg. Volume (3M) | 1,589,795 |
| Market Cap | 9,933,893,632 |
| Price / Book | 16.28 |
| 52 Weeks Range | |
| Earnings Date | 23 Mar 2026 |
| Operating Margin (TTM) | -4,865.98% |
| Diluted EPS (TTM) | -3.45 |
| Quarterly Revenue Growth (YOY) | -17.40% |
| Total Debt/Equity (MRQ) | 269.12% |
| Current Ratio (MRQ) | 1.25 |
| Operating Cash Flow (TTM) | -152.60 M |
| Levered Free Cash Flow (TTM) | -87.22 M |
| Return on Assets (TTM) | -48.60% |
| Return on Equity (TTM) | -196.12% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Abivax SA | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Institutions | 50.19% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Darwin Global Management, Ltd. | 31 Dec 2025 | 3,178,501 |
| Caligan Partners Lp | 31 Dec 2025 | 1,451,924 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 150.00 (BTIG, 19.40%) | Buy |
| Median | 142.50 (13.43%) | |
| Low | 131.00 (Citizens, 4.27%) | Buy |
| Average | 141.50 (12.63%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 116.65 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 09 Jan 2026 | 145.00 (15.42%) | Buy | 114.40 |
| BTIG | 08 Jan 2026 | 150.00 (19.40%) | Buy | 115.49 |
| Citizens | 16 Dec 2025 | 131.00 (4.27%) | Buy | 110.98 |
| Truist Securities | 24 Nov 2025 | 140.00 (11.44%) | Buy | 125.71 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 07 Jan 2026 | Announcement | Abivax Provides 2026 Corporate Outlook |
| 18 Dec 2025 | Announcement | Abivax to be Added to Nasdaq Biotechnology Index |
| 17 Dec 2025 | Announcement | Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings |
| 15 Dec 2025 | Announcement | Abivax Presents Third Quarter 2025 Financial Results |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |